DelMar Pharmaceuticals' lead-product cancer treatment granted 'Fast Track' designation by US FDA

VAL-083 is a potential new treatment for recurrent glioblastoma (rGBM), a cancer of the brain and spinal cord
Cancer
‘Fast Track’ designation helps expedite the review of drugs showing promise in treating life-threatening diseases

Shares of DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) surged almost 50% higher in premarket trading after the biopharmaceutical company said its lead-product cancer treatment, VAL-083, was granted 'Fast Track' designation by the US Food and Drug Administration.

VAL-083 is a potential new treatment for recurrent glioblastoma (rGBM), a cancer of the brain and spinal cord.

‘Fast Track’ designation helps expedite the review of drugs showing promise in treating life-threatening diseases.

The firm’s interim chief executive, Saiid Zarrabian commented: "We are enthusiastic about the potential of VAL-083 to offer a meaningful clinical benefit to patients with rGBM and for the opportunity to expedite the regulatory process through the FDA's Fast Track program."

In pre-market trading, DelMar shares were 46% higher at US$1.20.

View full DMPI profile View Profile

DelMar Pharmaceuticals Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline
Copyright © 2ndrangers.us, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.